Our commitment to women's health
Janssen-Cilag offers one of the most comprehensive product lines of oral contraceptives and other women's healthcare products available worldwide, including treatment for vaginal infections and menopause.

Vaginal infections
Candidosis is by far the most frequent of all forms of vaginal infections and Candida albicans is the most common yeast species involved. Sometimes other members of the genus cause infections. It is important that the correct diagnosis is made to distinguish Candida infections from other causes of vaginitis.

In 1967 Janssen researchers synthesised GYNO-DAKTARIN™ (miconazole nitrate), a broad-spectrum antimycotic. It provides rapid relief of symptoms. Janssen-Cilag's more recent discovery, SPORANOX™ (itraconazole) has been developed as an oral broad-spectrum antifungal agent when oral treatment is more appropriate than topical treatment.

Reproductive health
Janssen-Cilag has a long-standing tradition in the field of reproductive health. Among other products, our RWJPRI researchers have developed the oral contraceptives CILEST™, OVYSMEN™, and TRINOVUM™. The active substances in these products inhibit the release of natural hormones by the ovaries, thereby preventing ovulation. Oral contraceptives are probably one of the most extensively studied medications in history. Twenty years of research has brought safer pills and a long list of guidelines to help doctors screen out women most likely to develop serious complications.

Menopause
Menopause is an event common to all women, yet it is a highly individualised experience. Some women notice little difference in their bodies or moods, while others find the change extremely bothersome and disruptive. Menopausal research has been going on for at least 20 years, although progress has been substantial in the more recent years. Several large studies are currently attempting to resolve the remaining questions about the menopause and its biology, although it will take several more years to reach any definitive answers.

RWJPRI scientists have developed an impressive track record of pioneering innovative products for treating the undesirable effects of menopause. Our most widely used product in this field is SYSTEN™ (oestradiol), also known as EVOREL™ or EVOPAD™, a so-called hormone replacement therapy (HRT). SYSTEN™ comes as a patch, which is simply stuck onto the skin. New HRT treatments are being developed, including SYSTEN CONTI™ and SYSTEN SEQUI™.

Hormone replacement therapy is designed to bring back the natural level of sex hormones, which the body itself no longer produces, to that of before the menopause, thereby relieving the typical symptoms of the menopause. In addition, oestrogen therapy has a natural slowing effect on bone loss.